NCT01957007

A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC

A Phase 1b Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 34 (estimated)
• Sponsor: OncoMed Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of vantictumab when combined with docetaxel.

Detailed description

Once the maximum tolerated dose (MTD) or maximum administered dose (MAD) has been determined, up to 10 patients may be enrolled in the cohort-expansion phase to better characterize the safety, tolerability and PK of vantictumab combined with docetaxel. Up to approximately 34 patients may be enrolled into the study.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	Docetaxel	Docetaxel will be administered IV.
DRUG	vantictumab	Vantictumab will be administered intravenously

Timeline

• Start date: 2013-09-01
• Primary completion: 2016-12-01
• Completion: 2017-06-01
• First posted: 2013-10-08
• Last updated: 2020-09-09

Locations

3 sites across 1 country: United States